TAFA 93
Alternative Names: TAFA93Latest Information Update: 27 Sep 2013
At a glance
- Originator Isotechnika
- Class Small molecules
- Mechanism of Action MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 27 Sep 2013 Discontinued - Phase-I for Transplant rejection in Canada (PO)
- 27 Sep 2013 Discontinued - Phase-I for Transplant rejection in USA (PO)
- 31 Dec 2010 No development reported - Phase-I for Transplant rejection in Canada (PO)